IP Library Granted Patent US 8,026,083
Granted Patent B2
US 8,026,083 · App. 12/062,469 · Granted Sep 27, 2011

Patent

Assignees: Oxyrane UK Limited; VIB vzw; Universiteit Gent
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,026,083
App. No.
12/062,469
Granted
Sep 27, 2011
Kind
B2
Abstract

Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.

Claims (28)

1. An isolated nucleic acid comprising:

(a) the nucleotide sequence set forth in SEQ ID NO:1;

(b) a nucleotide sequence that hybridizes under highly stringent conditions to the complement of the nucleotide sequence set forth in SEQ ID NO:1; or

(c) the complement of the nucleotide sequence set forth in SEQ ID NO:1.

2. A vector comprising the nucleic acid sequence of claim 1 .

3. A cultured cell comprising the vector of claim 2 .

4. The cultured cell of claim 3 , wherein said cell is a fungal cell.

5. The cultured cell of claim 4 , wherein said fungal cell is Yarrowia lipolytica or Arxula adeninivorans.

6. An isolated nucleic acid comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO:1.

7. A vector comprising the nucleic acid of claim 6 .

8. A cultured cell comprising the vector of claim 7 .

9. The cultured cell of claim 8 , wherein said cell is a fungal cell.

10. The cultured cell of claim 9 , wherein said fungal cell is Yarrowia lipolytica or Arxula adeninivorans.

11. The nucleic acid of claim 6 , wherein said nucleotide sequence is at least 95% identical to SEQ ID NO:1.

12. An isolated nucleic acid comprising:

(a) the nucleotide sequence set forth in SEQ ID NO:2;

(b) a nucleotide sequence that hybridizes under highly stringent conditions to the complement of SEQ ID NO:2; or

(c) the complement of the nucleotide sequence set forth in SEQ ID NO:2.

13. A vector comprising the nucleic acid of claim 12 .

14. A cultured cell comprising the vector of claim 13 .

15. The cultured cell of claim 14 , wherein said cell is a fungal cell.

16. The cultured cell of claim 15 , wherein said fungal cell is Yarrowia lipolytica or Arxula adeninivorans.

17. An isolated nucleic acid comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO:2.

18. A vector comprising the nucleic acid of claim 17 .

19. A cultured cell comprising the vector of claim 18 .

20. The cultured cell of claim 19 , wherein said cell is a fungal cell.

21. The cultured cell of claim 20 , wherein said fungal cell is Yarrowia lipolytica or Arxula adeninivorans.

22. The isolated nucleic of claim 17 , wherein said nucleotide sequence is at least 95% identical to SEQ ID NO:2.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2024
From: OXYRANE UK LTD
To: VIB VZW
Reel/Frame 067265/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2011
From: CALLEWAERT, NICO LUC MARC; VERVECKEN, WOUTER; DE POURCQ, KAREN JACQUELINE MARCEL; GEYSENS, STEVEN CHRISTIAN JOZEF; GUERFAL, MOUNA
To: OXYRANE UK LIMITED; VIB VZW; UNIVERSITEIT GENT
Reel/Frame 026695/0468 →
Continuity (3)
Provisional Application 60909904 · Apr 3, 2007
Provisional Application 60940212 · May 25, 2007
Related Publication 20090069232A1 · Mar 12, 2009